All News
Filter News
Found 99 articles
-
Cerevance Announces Presentation of Preclinical Data During the Cold Spring Harbor Laboratory (CSHL) Neurodegenerative Diseases - Biology and Therapeutics Conference and Publication in Neuropharmacology
11/30/2022
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced the presentation of preclinical data supporting the use of the company’s Nuclear Enriched Sort sequencing (NETSseq) technology platform to identify novel, druggable targets involved in the regulation of neuroinflammation in Alzheimer’s disease (AD).
-
Cerevance Announces Presentation of Preclinical Study Results at the Society for Neuroscience Conference
11/15/2022
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, announced the presentation of preclinical study results during the poster session held November 14th at the Society for Neuroscience (SFN) 2022 conference in San Diego, California.
-
Cerevance to Present at the Society for Neuroscience (SFN) 2022
11/7/2022
Cerevance today announced a poster presentation at the Society for Neuroscience (SFN) 2022 conference, to be held in San Diego, California and virtually on November 12-16, 2022.
-
Movers & Shakers: New C-Suites for Assembly Biosciences, Urica Therapeutics, BlueSphere Bio and More
10/7/2022
Life sciences and biopharma companies added new CEOs, CMOs and CSOs to guide their companies into the future and oversee developmental programs. -
Cerevance Appoints Ottavio V. Vitolo, M.D., as Chief Medical Officer
10/3/2022
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, announced the appointment of Ottavio V. Vitolo, M.D. as chief medical officer.
-
BioSpace spoke with industry executives and investors about the current economic situation in the biotech industry and sourced tips on how leaders can weather the downturn.
-
Merck and Orna will explore various therapeutic and vaccine programs in a collaboration worth a potential $3.5 billion.
-
Using Cerevance’s proprietary NNETSseq technology platform, Merck and Cerevance have partnered to identify new targets for the treatment of Alzheimer’s disease.
-
Cerevance Establishes Strategic Research Collaboration with Merck for the Discovery of Novel Targets in Alzheimer’s Disease
8/9/2022
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced a multi-year strategic research collaboration with Merck, known as MSD outside the United States and Canada, to identify novel targets for Alzheimer’s disease utilizing Cerevance’s proprietary Nuclear Enriched Transcript Sort sequencing (NETSseq) technology platform.
-
Cerevance to Participate in Panel Discussion During the 2022 BIO International Convention
6/8/2022
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, announced that Craig Thompson, chief executive officer of Cerevance, will participate in a panel discussion during the 2022 BIO International Convention being held in San Diego, CA, June 13-16.
-
Biopharma and life sciences organizations strengthen their leadership teams and boards with these Movers & Shakers.
-
Cerevance Announces Leadership Transition to Implement Next Phase of Growth in Advancing Novel Therapeutics for Brain Diseases
4/19/2022
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, today announced the appointment of Craig Thompson to chief executive officer.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Cerevance reported positive clinical trial results for CVN424, an experimental treatment for Parkinson’s disease.
-
Cerevance Reports Positive Phase 2 Clinical Trial Results with CVN424, a Parkinson’s Disease Drug Working Through a New Mechanism
3/31/2022
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, today announced the completion of its Phase 2 clinical trial of CVN424, the company’s first-in-class, once-a-day, orally-delivered compound in development for the treatment of Parkinson’s disease.
-
Clinical trial news definitely picked up this final week of January. Here’s a look.
-
Cerevance Doses First Subjects in Phase 1 Clinical Trial of CVN766Study will evaluate safety and pharmacokinetics of potential treatment for psychiatric disorders
1/25/2022
Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system diseases, today announced the dosing of the first human subjects in a Phase 1 clinical trial of its compound, CVN766.
-
Many big companies, including Amgen, Moderna, Roche and Novartis, had already decided not to attend in-person and the sentiment was leaning that way.
-
Neurona Therapeutics Appoints Brad Margus to its Board of Directors
10/20/2021
Neurona Therapeutics, a biotherapeutics company advancing restorative neural cell therapies for the treatment of chronic neurological disorders, today announced that it has appointed Brad Margus to its board of directors.
-
BioSpace Movers & Shakers, Sept. 10
9/10/2021
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.